{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T01:36:32Z","timestamp":1775525792010,"version":"3.50.1"},"reference-count":73,"publisher":"Informa UK Limited","issue":"14","funder":[{"name":"the International Committee of Medical Journal Editors"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Microbiol."],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.2217\/fmb-2020-0182","type":"journal-article","created":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T10:45:17Z","timestamp":1600771517000},"page":"1319-1333","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Omadacycline: A Therapeutic Review of use in Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections"],"prefix":"10.1080","volume":"15","author":[{"given":"Teena","family":"Chopra","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Wayne State University,\rDetroit,\rMI\r42801,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avnish","family":"Sandhu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Wayne State University,\rDetroit,\rMI\r42801,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolette","family":"Theriault","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, GST Micro LLC,\rRichmond,\rVA\r23231,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joni","family":"Meehan","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, GST Micro LLC,\rRichmond,\rVA\r23231,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2221-008X","authenticated-orcid":false,"given":"Glenn","family":"Tillotson","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, GST Micro LLC,\rRichmond,\rVA\r23231,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,9,22]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-018-0147-4"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2012.08.003"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00020-18"},{"key":"e_1_3_3_6_1","unstructured":"Siddiqui A KoiralaJ. Methicillin Resistant Staphylococcus Aureus (MRSA). StatPearls Publishing FL USA (2020)."},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/2049936117723228"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2012.103"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2012.03.013"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.15620\/cdc:82532"},{"key":"e_1_3_3_11_1","volume-title":"Antimicrobial Resistance: Global Report on Surveillance.","author":"World Health Organization","year":"2014","unstructured":"World Health Organization . Antimicrobial Resistance: Global Report on Surveillance.World Health Organization, Geneva2014."},{"key":"e_1_3_3_12_1","unstructured":"U.S. Food and Drug Administration . Omadacycline Injection and Oral Products Package Insert (2019). http:\/\/www fda.gov\/media\/115100"},{"key":"e_1_3_3_13_1","volume-title":"Contagion Live.","author":"Fleming M","year":"2018","unstructured":"Fleming M . FDA Approves Omadacycline for ABSSSI and CABP. Contagion Live.Contagion\u00aeNJ, USA (2018).,"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics5040032"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01066-13"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01242-13"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01536-15"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2016.07.029"},{"key":"e_1_3_3_19_1","volume-title":"The Interscience Conference of Antimicrobial Agents and Chemotherapy","author":"Ruzin A","year":"2010","unstructured":"Ruzin A , Dzink-FoxJ, JonesA, DeanC, BradfordPA. Studies on the mechanism of resistance to PTK796 in Pseudomonas aeruginosa and Klebsiella pneumoniae. Presented at: The Interscience Conference of Antimicrobial Agents and ChemotherapyMA, USA, 12\u201315September2010(Poster CI-1413)."},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz394"},{"key":"e_1_3_3_21_1","volume-title":"The ASM Microbe.","author":"Dubois J","year":"2016","unstructured":"Dubois J , DuhoisM, MartelJ, ThnakaS. In vitro intracellular activity of omadacycline against Legionella pneumophila. Presented at: The ASM Microbe.MA, USA, 16\u201320 June 2016 (Abstract 551)."},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02327-17"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02411-16"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.11604\/pamj.2017.27.66.10226"},{"key":"e_1_3_3_25_1","volume-title":"Results from the SENTRY Antimicrobial Surveillance Program paper presented at the European Congress of Clinical Microbiology & Infectious Diseases","author":"Huband MD","year":"2017","unstructured":"Huband MD , RhombergPR, SaderHS, SchuchertJE, FlammRK. In vitro Activity of omadacycline and comparators against gram-negative bacterial isolates collected from patients in European Medical Centres (2016). Results from the SENTRY Antimicrobial Surveillance Program paper presented at the European Congress of Clinical Microbiology & Infectious DiseasesVienna, Austria, 2017."},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2016-0100"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01734-16"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01907-18"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02522-18"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00047-18"},{"key":"e_1_3_3_31_1","volume-title":"The European Congress of Clinical Microbiology & Infectious Diseases","author":"Macone AB","year":"2011","unstructured":"Macone AB , DonatelliJE, DraperMP, TanakaSK. Poster No. P1141. In vitro activity of omadacycline (PTK796) in broth, broth plus lung surfactant or human serum. Paper presented at: The European Congress of Clinical Microbiology & Infectious DiseasesMilan, Italy, 7\u201310 May 2011."},{"key":"e_1_3_3_32_1","volume-title":"The ASM Microbe.","author":"Villano S","year":"2016","unstructured":"Villano S , TzanisE, TanakaSK. In Vitro Protein binding with Omadacycline, a first in class aminomethylcycline antibiotic abstract No. 518. Presented at: The ASM Microbe.MA, USA, 16\u201320 June 2016."},{"key":"e_1_3_3_33_1","volume-title":"The European Congress of Clinical Microbiology and Infectious Diseases","author":"Thwaites M","year":"2017","unstructured":"Thwaites M , ShinabargerD, PillarC. The impact of non-standard test conditons on the in vitro activity of omadacycline by broth microdilution. Presented at: The European Congress of Clinical Microbiology and Infectious DiseasesVienna, Austria, 22\u201325 April 2017 (Abstract Pl263)."},{"key":"e_1_3_3_34_1","doi-asserted-by":"crossref","unstructured":"Dubois J DuboisM MartelJ SteenbergenJ. In vitro extracellular and intracellular activity of omadacycline against Staphylococcus aureus paper presented at the European Conference of Clinical Microbiology and Infectious Diseases. Vienna Austria (2017).","DOI":"10.26226\/morressier.56d6be7ad462b80296c97ddc"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.814"},{"key":"e_1_3_3_36_1","volume-title":"Pharmacology and Pharmacotherapeutics, Volume 1.","author":"Satoskar RS","year":"1973","unstructured":"Satoskar RS , BhandarkarSD, NirmalaNR. Pharmacology and Pharmacotherapeutics, Volume 1.Popular Prakashan (1973)."},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01784-16"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2016.1213465"},{"key":"e_1_3_3_39_1","volume-title":"European Congress of Clinical Microbiology and Infectious Diseases.","author":"Tanaka SK","year":"2016","unstructured":"Tanaka SK , VillanoS, TzanisE. Single and multiple dose pharmacokinetics and tolerability of intravenous omadacycline in healthy volunteers. Presented at: European Congress of Clinical Microbiology and Infectious Diseases.Amsterdam, The Netherlands (2016) (poster no. 1319)."},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz309"},{"key":"e_1_3_3_41_1","unstructured":"Paratek Pharmaceuticals Inc . NUZYRA (omadacycline). Package Insert for oral and intravenous use. MA USA (2019)."},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01487-17"},{"key":"e_1_3_3_43_1","article-title":"Oral omadacycline vs. oral linezolid for the treatment of ABSSSI","author":"National Library of Medicine","year":"2018","unstructured":"National Library of Medicine . Oral omadacycline vs. oral linezolid for the treatment of ABSSSI. NCT02877927 ClinicalTrials.gov (2018). clinicaltrials.gov\/ct2\/results?cond=term=NCT+02877927&cntry=&state=&city=&dist","journal-title":"NCT02877927 ClinicalTrials.gov"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01393-16"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01135-17"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02263-19"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02083"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800201"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00948-12"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800170"},{"key":"e_1_3_3_51_1","volume-title":"The European Congress of Clinical Microbiology and Infectious Diseases","author":"Hawser S","year":"2016","unstructured":"Hawser S , SiegmundC, JeandeyPet al. Bactericidal activity of omadacycline, a novel aminomethylcycline. Presented at: The European Congress of Clinical Microbiology and Infectious DiseasesAmsterdam, The Netherlands, 9\u201312 April 2016 (Abstract no. B22. Poster no. P1322)."},{"key":"e_1_3_3_52_1","volume-title":"Presented at the ASM Microbe.","author":"Hinshaw R","year":"2016","unstructured":"Hinshaw R , StapertL, ShinabargerD, PillarC. Post-antibiotic effect of omadacycline against target pathogens. Presented at the ASM Microbe.MA, USA, 16\u201320 June 2016 (Abstract no. 512)."},{"key":"e_1_3_3_53_1","volume-title":"The American Society of Microbiology (ASM) Microbe","author":"Diehl D","year":"2016","unstructured":"Diehl D , BiondaN, CadyNC, StricklandAD, TanakaSK. In vitro activity of omadacycline against E. coli biofilms. Presented at: The American Society of Microbiology (ASM) MicrobeMA, USA, June 16\u201320, 2016 (Abstract no. 552)."},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.5301\/ijao.5000027"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg267"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01581-18"},{"key":"e_1_3_3_57_1","volume-title":"Interscience Conference of Antimicrobial Agents and Chemotherapy.","author":"Craig WA","year":"2006","unstructured":"Craig WA , AndesD, OdinecsA. In vivo pharmacodynamics of MK-2764 \/ PTK 0796 against various Gram-positive and Gram-negative bacteria in the thighs of neutropenic and normal mice. Presented at: Interscience Conference of Antimicrobial Agents and Chemotherapy.CA, USA (2006) (Poster no. F1-1974. Abstract 1875)."},{"key":"e_1_3_3_58_1","volume-title":"The European Congress of Clinical Microbiology and Infectious Disease.","author":"Endermann R","year":"2004","unstructured":"Endermann R , LadelCH, Broetz-OesterheltH, LabischinskiH, WuppertalD. BAY 73-7388 is highly efficacious in animal models of intraabdominal infections caused by a range of aerobic and anaerobic organisms, including VRE. Paper presented at: The European Congress of Clinical Microbiology and Infectious Disease.Prague, Czech Republic, 1\u20134 May 2004 (Abstract P928)."},{"key":"e_1_3_3_59_1","volume-title":"The Interscience Congress on Antimicrobial Agents and Chemotherapy","author":"McKenney D","year":"2003","unstructured":"McKenney D et al. Evaluation of PTK 0796 (BAY 73-6944) in experimental models of infections caused by Gram-positive and Gram-negative pathogens. Presented at: The Interscience Congress on Antimicrobial Agents and Chemotherapy. IL, USA2003 (Abstract no. 2627. Poster no. F-757)."},{"key":"e_1_3_3_60_1","volume-title":"The European Congress of Clinical Microbiology and Infectious Diseases","author":"Kim O","year":"2016","unstructured":"Kim O et al. Activity and efficacy of omadacycline against Clostridium difficile. The European Congress of Clinical Microbiology and Infectious Diseases. Paper presented at: Amsterdam, The Netherlands9\u201312 April 2016 (Abstract no. P1325)."},{"key":"e_1_3_3_61_1","volume-title":"The American Society of Microbiology (ASM) Microbe","author":"Overcash JS","year":"2017","unstructured":"Overcash JS et al. Pharmacokinetics and safety of omadacycline in patients with uncomplicated urinary tract infections. Paper presented at: The American Society of Microbiology (ASM) Microbe. LA, USA1\u20135 June 2017 (Abstract no. 200)."},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02057-17"},{"key":"e_1_3_3_63_1","volume-title":"The Interscience Conference of Antimicrobial Agents and Chemotherapy","author":"Ting L","year":"2012","unstructured":"Ting L et al. Pharmacokinetics of omadacycline (PTK0796) in subjects with hepatic impairment. Paper presented at: The Interscience Conference of Antimicrobial Agents and ChemotherapyCA, USA, 9\u201312 September 2012. (Abstract 1282. Poster A-1282)."},{"key":"e_1_3_3_64_1","unstructured":"European Medicines Agency . Withdrawal assessment report: nuzyra (omadacycline tosylate). EMA Amsterdam The Netherlands (2020)."},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2185"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz397"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30275-0"},{"key":"e_1_3_3_68_1","unstructured":"Early and effective clinical success in ABSSSI-NUZYRA (Internet). Paratek Pharmaceuticals Inc. Boston MA USA 2018 (cited August 3 2019). https:\/\/www.nuzyra.com\/hcp\/efficacy\/absssi"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz396"},{"key":"e_1_3_3_70_1","doi-asserted-by":"crossref","unstructured":"File TM Cure-BoltN ChitraS TzanisE McGovernPC. Efficacy and safety of omadacycline in chronic kidney disease (CKD) patients with acute bacterial skin and skin structure infections (ABSSSI): a subgroup analysis from the OASIS trial presented at the ID Week. San Diego CA USA (4\u20138 October 2017).","DOI":"10.1093\/ofid\/ofx163.1364"},{"key":"e_1_3_3_71_1","volume-title":"ID Week.","author":"Ohl CA","year":"2017","unstructured":"Ohl CA , Cure-BoltN, ChitraS, TzanisE, McGovernPC. Efficacy and safety of omadacycline in intravenous drug using (IVDA) and hepatitis C-positive (HCV+) patients with acute bacterial skin and structure infections (ABSSSI): a subgroup analysis from the OASIS trial. Presented at: ID Week.CA, USA,2017 (poster no. 1885)."},{"key":"e_1_3_3_72_1","volume-title":"The ID week","author":"Darpo B","year":"2017","unstructured":"Darpo B , TzanisE, Garrity-RyanLet al. Cardiac safety of omadacycline in the IV\/oral Phase III acute bacterial skin and skin structure (ABSSSI) and in the IV\/oral Phase III community-acquired bacterial pneumonia (CABP) studies. Presented at: The ID weekCA, USA2017 (Poster no. 1886)."},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz004"},{"key":"e_1_3_3_74_1","unstructured":"National Library of Medicine . Clinical Trial NCT03757234: IV or IV\/PO Omadacycline vs. IV\/PO levofloxacin for the treatment of acute pyelonephritis (2019)."},{"key":"e_1_3_3_75_1","unstructured":"National Library of Medicine . Clinical Trial NCT03425396: oral omadacycline vs. oral nitrofurantoin for the treatment of cystitis (2019)."}],"container-title":["Future Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fmb-2020-0182","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:39:57Z","timestamp":1719124797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fmb-2020-0182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":73,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.2217\/fmb-2020-0182"],"URL":"https:\/\/doi.org\/10.2217\/fmb-2020-0182","relation":{},"ISSN":["1746-0913","1746-0921"],"issn-type":[{"value":"1746-0913","type":"print"},{"value":"1746-0921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-07-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}